Pasar al contenido principal

GELISOME: FORMULACIÓN NANOSTRUCTURADA PARA CICATRIZACIÓN DEL TEJIDO CUTÁNEO

CPP2021-008954

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Transferencia de Conocimiento
Convocatoria Proyectos en Colaboración Público-Privada
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario BICOSOME SL

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Lipid-Based Gels for Delivery of 3-O-Ethyl L-Ascorbic acid in Topical Applications

  • Loza-Rodríguez, Noèlia
  • Millán-Sánchez, Aina
  • Mallandrich, Mireia
  • Calpena, Ana Cristina
  • López, Olga
This study explores the incorporation of 10% 3-O-ethyl L-ascorbic acid (ETVC), a derivative of vitamin C, into two lipid gel systems: a hydrogel (HG) consisting exclusively of lipids and water and a bigel (BG) combining the hydrogel with an oleogel made from olive oil and beeswax. We investigated the ETVC release profiles from both materials using synthetic membranes and measured their permeation through porcine skin in vitro. Additionally, the interaction of these lipid gel systems with the stratum corneum (SC) was determined. Results from the release study indicate that the BG exhibited slower ETVC release compared to the HG. The permeation experiments showed that the presence of lipids in the formulations enhanced ETVC retention in the skin. The HG delivered a higher amount to the SC, while the BG achieved greater retention in the epidermis. This difference is attributed to the different lipophilic nature of each material. The structural analysis of SC lipids revealed that the organization of surface lipids remained unaltered by the application of the gels. Finally, an in vitro efficacy test in porcine skin using methylene blue indicated that our ETVC gels exhibited antioxidant activity. These findings provide valuable insights into the potential of lipidbased gels for topical applications, This work was supported by funds from the Spanish Ministry of Science and Innovation with Ayudas para contratos para la formación de doctores en empresas “Doctorados Industriales”, DIN2019-010777, Bicosome S.L., the Mechanism for the Recovery and Resilience of the European Union and MICINN with the CPP2021-008954 project and PID2021-124848OB-I00 project, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Evaluation of Preclinical Efficacy of Curcumin-Loaded Bicosome Systems in Amelioration of Oral Mucositis

  • Vergara, Daniela
  • Sanhueza, Claudia
  • Méndez, Susana
  • Bustamante, Mariela
  • Vega, Benjamín
  • Acevedo, Francisca
  • López, Olga
[Background/Objectives] Oral mucositis (OM) is a common and debilitating side effect of cancer therapy, characterized by ulceration or inflammation of the oral mucosa. This study evaluates the preclinical efficacy of curcumin-loaded bicosome systems (cur-BS) in mitigating chemotherapy-induced OM in mice., [Methods] BS were prepared using a combination of 1,2-di-palmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2-dihexanoyl-sn-glycero-3-phosphocholine (DHPC), α-tocopherol, and curcumin, encapsulated within liposomal vesicles. Three formulations with different curcumin concentrations (180, 540, and 900 μM) were characterized by particle size, polydispersity index (PDI), encapsulation efficiency (EE), appearance, and morphology. The formulation with the highest concentration (cur-BS 5×) was selected for ex vivo permeability studies, release profile analysis, and in vitro anti-inflammatory efficacy. OM was induced in mice using 5-fluorouracil (5-FU) and acetic acid. Cur-BS 5× was compared to the commercial product Dentoxol®. Results: The results showed that cur-BS 5× provided sustained release through a mechanism involving both diffusion and matrix relaxation, enhancing curcumin retention in deeper skin layers. Treatment with cur-BS 5× downregulated the expression of inflammatory markers (IL-1β and TNF-α). Macroscopic assessments demonstrated that both cur-BS 5× and Dentoxol® reduced OM severity, with the greatest improvement observed between days 6 and 9. By day 24, OM scores were 1.25 ± 0.5 for cur-BS 5× and 1.0 ± 0.0 for Dentoxol®, indicating effectiveness in both treatments. However, histological analysis revealed superior tissue recovery with cur-BS 5×, showing better epithelial structure and reduced inflammation. Cur-BS 5×-treated mice also exhibited greater weight recovery and higher survival rates compared to the Dentoxol® group., [Conclusions] These findings suggest that cur-BS 5× may enhance OM treatment, offering outcomes comparable to or better than those of Dentoxol®., This research was funded by the Agencia Nacional de Investigación y Desarrollo (ANID) from the Chilean Government through FONDECYT Postdoctoral Project No. 3210533. The Mechanism for the Recovery and Resilience of the European Union and MICINN with the CPP2021-008954 project, PID2021-124848OB-I00 project, and ANID-Milenio-NCN2023_054 project., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A lipid hydrogel to transport and release an anti-HIV-1 peptide into vaginal mucosa

  • Loza-Rodríguez, Noèlia
  • Millán-Sánchez, Aina
  • Benítez, Aleix
  • Pons Pons, Ramon
  • Gómara Elena, María José
  • Haro Villar, Isabel
  • Genescà, Meritxell
The cervicovaginal mucosa is a main portal of entry for the human immunodeficiency virus (HIV). Peptide antiretroviral therapy is a promising treatment to decrease the HIV infection rate, but yet it presents several weaknesses such as poor bioavailability, development of drug resistance and poor ability to reach the mucosal tissue with the effective concentration. In this work, an HIV inhibitor peptide (RE-E1P47) was encapsulated into a lipidic hydrogel (HG) to test its capacity to deliver the peptide to mucosa ex vivo and its pre-exposure prophylactic efficacy to inhibit or limit HIV infection. The proposed HG is made only with lipids and water and has a composition similar to the vaginal fluid that naturally covers the mucosa. Characterization studies with confocal microscopy, ATR-FTIR, SAXS and WAXS reveal that peptide incorporation does not alter the hydrogel's micro- and nanostructure. Permeation and diffusion tests confirm peptide delivery to the surface layers of the mucosal tissue without interaction or diffusion into a vaginal fluid simulant (VFS). Importantly, efficacy studies demonstrate a significant reduction in HIV infection rates of 60% after HG treatment. Thus, we highlight this material formulation as a strong candidate for mucosal topical application, particularly in the development of pre-exposure prophylaxis (PrEP) treatments against HIV-1., This work was supported by funds from the Spanish Ministry of Science and Innovation with Ayudas para contratos para la formación de doctores en empresas “Doctorados Industriales”, DIN2019-010777, Bicosome S. L., the Mechanism for the Recovery and Resilience of the European Union and MICINN with the CPP2021-008954 project and PID2021-124848OB-I00 project. This work was also supported by grants from the Spanish Health Institute Carlos III (ISCIII, PI20/00160), cofunded by ERDF/ESF, “A way to make Europe”/“Investing in your future”, from MCIN/AEI/10.13039/501100011033 and the European Union “Next Generation EU”/PRTR (CNS2022-135549 and PID2023-149204OB-I00), the Fundació La Marató TV3 (201814-10 FMTV3) and Gilead fellowships (GLD21/00049 and GLD23/00012) to M. G. M. J. G. and I. H. acknowledge the Grant PID2021-122216-OB-I00 received from the Spanish Ministry of Science, Innovation and Universities and the European Regional Development Fund., Peer reviewed